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Abstract
Background: Since Oberndorfer proposed the term "carcinoid" in 1907, over 100 years have
passed. This attractive term was initially proposed for 6 cases of his own experience with 12
submucosal lesions in the small intestine.
Oberndorfer summarized the characteristic features of these lesions as follows: (1) small in size
and often multiple, (2) histologically undifferentiated with a suggestion of gland-formation, (3) well-
defined without any tendency to infiltrate the surroundings, (4) no metastases, and (5) apparently
slow-growing reaching no significant size with a seemingly harmless nature.
Review: This article stresses the malignant nature of "carcinoid" on the basis of local invasion prior
to metastases in the first two sessions, (1) with Oberndorfer's original diagram, and (2) with an
experimental observation on extraglandular microcarcinoid in a form of "budding".
Next, (3) a statistical comparison between a carcinoid group and a non-carcinoid ordinary
carcinoma group is introduced on metastasis rates at an early stage with two prescribed factors of
the depth of invasion restricted within the submucosa (sm-lesion) and a small tumor size category
of 1 cm to 2 cm: the carcinoid group exhibited metastasis rates higher than those in the ordinary
carcinoma group when calculated in the stomach and rectum.
In the author's experience, "carcinoids" are malignant not only in the gastrointestinal tract but also
in the other sites on the basis of local invasion.
Lastly, (4) discussion on the terminology of "carcinoid" as a misnomer is carried out.
Adequate terms referring to the entity of this malignant tumor group are discussed. One of the
most adequate and brief terms for "carcinoid" that is included now in neuroendocrine tumor group
would be "endocrinocarcinoma" as per the author's proposal, followed by NEC
(neuroendocrinocarcinoma) or GEC (gut endocrinocarcinoma).
Conclusion: The term "carcinoid" is a misnomer that can be confirmed on the basis of local
invasion prior to metastases. "No metastases without local invasion" is not of a negligible
importance.
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Background
Since Oberndorfer proposed the term "carcinoid" in
1907, over 100 years have passed. This attractive term was
initially used for 6 cases of his own experience with 12
submucosal lesions in the small intestine.
Oberndorfer summarized the characteristic features of
these lesions as follows: (1) small in size and often multi-
ple, (2) histologically undifferentiated with a suggestion
of gland-formation, (3) well-defined without any ten-
dency to infiltrate the surroundings, (4) no metastases,
and (5) apparently slow-growing reaching no significant
size with a seemingly harmless nature.
Review
Introduction
In this short article, the malignancy of carcinoids is
stressed on the basis of local invasion prior to metastase
in the first two sessions.
A statistical comparison of metastasis rates between a car-
cinoid group and a non-carcinoid ordinary carcinoma
group is introduced at an early stage with two prescribed
factors of the depth of invasion and a small tumor size cat-
egory.
Finally, the terminology of carcinoid as a misnomer is dis-
cussed.
Reevaluation of Oberndorfer's original diagram of 
"submucosal nodule"
Characteristic features of lesions described by Oberndor-
fer are well reflected in a beautiful and precise diagram in
Fig. 1 in his article [1], indicating a lesion involving a
small portion of the mucosa and a large space of the sub-
mucosa, the latter seemingly well-defined but without
encapsulation.
The findings of this lesion indicate, however, apparent
malignancy of the tumor with the small original site in the
mucosa invading down continuously into the submucosa
forming a larger submucosal nodule as a result. Thus, the
lesion is a malignant epithelial tumor, namely a carci-
noma, but not a "carcinoma-like" tumor of benign nature
that was initially described as a carcinoid.
Extraglandular microcarcinoid in a form of "budding"
All gastrointestinal "carcinoids" are malignant at their
very beginning, "budding" stage, of neoplastic formation.
The early developmental process of carcinoid formation
may be hypothetically divided into three stages as shown
in Table 1.
An observation on consecutive serial sections of the glan-
dular stomach of an experimental animal clearly indicates
that the extraglandular microproliferation of argyrophil
cells (IIIB) is a malignant lesion as a "microcarcinoid" at
its very beginning of neoplastic formation in a form of
"budding" as indicated in Fig. 3A–C in the article [2]. Such
a developmental process of invasion prior to metastases is
thought to be identical to the process in other organs not
only of the other sites of the gastrointestinal tract, but also
in other sites including the extradigestive organs.
A comparison of metastasis rates in early stage: sm-lesions 
of carcinoids and ordinary carcinomas
Malignancy represented by metastasis rates in early stages
with depth of invasion of the lesions restricted within the
submucosa (sm-lesion) is discussed in a statistical com-
parison between two groups of carcinoid (n = 1158) and
ordinary carcinoma (n = 1141) in Table 9 of the article [3].
In the stomach, the metastasis rates of the two groups of
carcinoid versus ordinary carcinoma are calculated as
21.4% versus 3.1% in the size range category of 10.1 mm
– 20.0 mm (p < 0.0001).
In the rectum, the metastasis rates of these two groups are
described as 27.6% versus 10.0% in the same size category
(p < 0.05), and as 32.4% versus 9.8% in the size range cat-
egory over 10.1 mm as a whole (p < 0.0001). These results
show that early stage carcinoids, with two prescribed fac-
tors of depth of invasion restricted within the submucosa
and tumor size range of 1 cm to 2 cm, metastasize earlier
than ordinary carcinomas with the identical description in
both the stomach and rectum.
Terminology
The term "carcinoid" has been deprecated by several
authors mostly based on the metastatic potentiality (Table
2), as unfortunate [4], misleading and unsafe [5], out-
moded [6,7], archaic [8,9], confusing [10], and even a
misnomer by some authors [3,11-15]. One of the most
adequate and brief terms for "carcinoid" that is included
now in the group of GEP-NETs (gastroenteropancreatc
neuroendocrine tumors) or simply NETs [8,16,17] would
be "endocrinocarcinoma" [18-21], followed by NEC
(neuroendocrinocarcinoma) or GEC (gut endocrinocarci-
noma).
Table 1: Microproliferation of argyrophil cells [2]
I Hyperplastic: Intraglandular
II Preneoplastic: Intraglandular
III Neoplastic
IIIa Intraglandular
IIIb Extraglandular ("budding": microinvasion)
Extraglandular neoplastic formation starts with a form of "budding" 
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On the other hand, since the term "carcinoid" has been so
attractive and popularly used on a worldwide scale, and
will be alive in the future for searching systems such as
PubMed or Index Medicus, it would be very difficult and
inconvenient to eliminate this term in a short period of
time. Meanwhile this term and a newly accepted term, if
decided, should be interchangeable with each other for
the purpose of automated searching: for a concrete exam-
ple, the new term with carcinoid in parentheses: [endo-
crinocarcinoma (carcinoid) ....].
Most important is that the term "carcinoid" should be
used for a certain number of years, at least during the
present generation of more or less 50 years, in the author's
estimation, and be described without an adjective
"benign" or "malignant" in recognition of the real entity
of this particular malignant tumor group. Then, the neces-
sity of the term "carcinoid" might be discussed by the next
generation concerning its usefulness in automated search-
ing for the literature.
No "benign" carcinoid without local invasion has been
available up to this date either in the digestive organs or
extradigestive sites in the author's experience.
Only complete serial sections of a seemingly encapsulated
lesion could prove the benignancy, if any, with definite
confirmation for the absence of a break of the capsule by
microinvasion or budding. This would be, however, prac-
tically impossible. The histologic patterns or classification
[11,14] would be still well applicable to "endocrinocarci-
noma" as an initial morphologic implication for diagno-
sis.
The adequate term should be globally and historically dis-
cussed on several proposals along with future problems in
relation to the real entity of this tumor group, considering
the evaluation of the Consensus Conference [17].
Changes in concepts of "carcinoid"
It is extraordinarily courageous to coin a new concept of
tumor entity, as did Oberndorfer, a 31-year-old enthusias-
tic young scientist at that time in the year 1907 [1], and
similarly to criticize a well-established and world-widely
accepted concept introduced even in the textbooks. How-
ever, a change corrected on the basis of the truth is always
required in science.
Conclusion
The term "carcinoid" is a misnomer: the malignancy of
this tumor group can be confirmed on the basis of local
invasion prior to metastases. "No metastases without
local invasion" is not of a negligible importance.
The adequate term should be globally and historically dis-
cussed in relation to the real entity of this tumor group,
considering the evaluation of the Consensus Conference.
Competing interests
The author has been retired from any institutional career
for almost four years, and he has no competing interests
of either a financial or a non-financial type in relation to
this manuscript.
Author's information
Recipient: (1) IRPC Eminent Scientist of the Year 2004:
World Scientists Forum International Awards in Surgery
and Surgical Pathology, 2004.
(2) ENETS Life Achievement Award and (3) IPSEN Obern-
dorfer Prize, at the 5th
ENETS in Paris, 2008.
IRPC: International Research Promoting Council.
ENETS: European Neuroendocrine Tumor Society.
IPSEN: Institut de Produits de Synthèse et d'Extraction
Naturelle.
NET: Neuroendocrine Tumor/NEC: Neuroendocrine Car-
cinoma.
Acknowledgements
The author appreciates the editorial understandings of the Journal of 
Experimental & Clinical Cancer Research for having given him the oppor-
tunity to propose this review article. The author's appreciation further 
extends to Mr. A. Suarez who made adjustments of English expressions in 
the manuscript.
References
1. Oberndorfer S: Karzinoide Tumoren des dündarms.  Frankf Z
Pathol 1907, 1:426-432.
2. Soga J, Kohro T, Tazawa K, Kanahara H, Sano M, Sakashita T, Tajima
K, Morooka H, Karaki Y: Argyrophil cell microneoplasia in Mas-
Table 2: the term "Carcinoid"
Evaluation Authors Year Reference
Unfortunate Willis RA 1940 [4]
Misleading Roberts TW 1958 [5]
Outmoded Wick MR, et al 1988 [6]
Klemm KK, et al 1999 [7]
Archaic Modlin IM, et al 1997 [8]
Modlin IM 2005 [9]
Confusing Andrés R 2002 [10]
Misnomer Soga J 1973 [11]
Rowe LD 1979 [12]
Moertel CG 1987 [13]
Soga J, et al 1999 [14]
Soga J 2003 [15]
Soga J 2005 [3]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Experimental & Clinical Cancer Research 2009, 28:15 http://www.jeccr.com/content/28/1/15
Page 4 of 4
(page number not for citation purposes)
tomys' stomach – An observation on early carcinoid forma-
tion.  J Natl Cancer Inst 1975, 55:1001-1006.
3. Soga J: Early-stage carcinoids of the gastrointestinal tract. An
analysis of 1914 reported cases.  Cancer 2005, 109:1587-1595.
4. Willis RA: Argentaffin carcinomata ("carcinoids") of the small
intestine.  Med J Aust 1940, 2:400-403.
5. Roberts TW: Argentaffin carcinoma arising in teratoma of
ovary.  Delaware State Med J 1958, 30:182-185.
6. Wick MR, Rosai J: Neuroendocrine neoplasms of the thymus.
Pathol Res Pract 1988, 183:188-199.
7. Klemm KM, Moran CA: Primary neuroendocrine carcinomas of
the thymus.  Semin Diag Pathol 1999, 16:32-41.
8. Modlin IM, Sandor A: An analysis of 8305 caes of carcinoid
tumor.  Cancer 1997, 79:813-829.
9. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD: Current sta-
tus of gastrointestinal carcinoids.  Gastroenterology 2005,
128:1717-1751.
10. Andrés R, Mayordomo JI, Cajal SR, Tres A: Cushing's syndrome
associated to locally advanced thymic carcinoid tumor.
Tumori 2002, 88:65-67.
11. Soga J: Carcinoids: Their changing concepts and a new histo-
logic classification.  In Gastro-Entero-Pancreatic System: A Cell-Biologi-
cal approach Edited by: Fujita T. Stuttgart: George Thieme (Verlag);
1973:101-119. 
12. Rowe LD, Jafek BW: Bronchial adenoma: A malignant misno-
mer.  Laryngoscope 1979, 89:1991-1999.
13. Moertel CG: Karnofsky memorial lecture. An Odyssey in the
land of small tumors.  J Clin Oncol 1987, 5:1503-1522.
14. Soga J, Yakuwa Y, Osaka M: A classification of problems regard-
ing gut endocrinomas (carcinoids and relevant neoplasms).  J
Exp Clin Cancer Res 1999, 18:5-12.
15. Soga J: Carcinoids and their variant endocrinomas. An analy-
sis of 11842 reported cases.  J Exp Clin Cancer Res 2003,
22:517-530.
16. Modlin IM, Öberg K, Chung DC, Jensen RT, de Herder WW, Thakker
RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nils-
son O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroentero-
pancreatic neuroendocrine tumours.  Lancet Oncol 2008,
9:61-72.
17. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM,
McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wieden-
mann B: TNM staging of midgut and hindgut (neuro) endo-
crine tumors: a consensus proposal including a grading
system.  Virchows Arch 2007, 451:757-762.
18. Soga J: Endocrinocarcinoma (carcinoids and their variants) of
the duodenum: an evaluation of 927 cases.  J Exp Clin Cancer Res
2003, 22:349-363.
19. Soga J, Ferlito A, Rinaldo A: Endocrinocarcinomas (carcinoids
and their variants) of the larynx: a comparative considera-
tion with those of other sites.  Oral Oncol 2004, 40:668-672.
20. Ferlito A, Rinaldo A: The spectrum of endocrinocarcinoma of
the larynx.  Oral Oncol 2005, 41:878-883.
21. Soga J: Gut-Pancreatic Endocarinomas – Endocrinocarcino-
mas: Carcinoids and their variant neoplasms.  3rd edition.
Kokodo-Co. Ltd., Niigata; 2004. 